Recursion Pharmaceuticals (NASDAQ: RXRX) didn't have a fine start to the working week on Monday, at least as far as its stock ...

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote ...

Q1 2025 Management View CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, ...